Diaxonhit Share Price Euronext Paris
Stocks
FR0004054427
Biotechnology & Medical Research
OTC Markets Traded| Market Cap | 21Cr 24Cr 20Cr 18Cr 34Cr 2.34TCr 35Cr 237.29Cr 93Cr 1.16TCr 92Cr 90Cr 3.99TCr | P/E 2026 * |
18.8x | P/E 2027 * | - |
|---|---|---|---|---|---|
| Enterprise Value | 18Cr 21Cr 17Cr 16Cr 29Cr 1.99TCr 30Cr 201.88Cr 79Cr 982.8Cr 78Cr 76Cr 3.4TCr | EV / Sales 2026 * |
1.04x | EV / Sales 2027 * | - |
| Free-Float |
98.24% | Yield 2026 * |
-
| Yield 2027 * | - |
| 1 day | -1.83% |
| Manager | Title | Age | Since |
|---|---|---|---|
Denis Fortier
CEO | Chief Executive Officer | 58 | 13/06/2023 |
Olivier Bosc
DFI | Director of Finance/CFO | - | 10/10/2023 |
Maarten Penning
CTO | Chief Tech/Sci/R&D Officer | - | 01/07/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 70 | 01/01/2019 | |
Michel Picot
BRD | Director/Board Member | 73 | 27/06/2019 |
| Director/Board Member | 69 | 15/06/2017 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.83% | -.--% | - | - | 24Cr | |
| -0.30% | -0.99% | -1.20% | +10.66% | 4.77TCr | |
| -0.61% | +4.26% | +396.16% | +647.20% | 4TCr | |
| 0.00% | +4.93% | +11.81% | +55.56% | 3.62TCr | |
| +2.48% | +4.57% | +7.05% | -5.05% | 3.56TCr | |
| +0.62% | +3.53% | +5.41% | +42.19% | 2.79TCr | |
| -0.17% | +0.66% | - | - | 1.67TCr | |
| -2.00% | +11.64% | +31.71% | +136.81% | 1.65TCr | |
| -0.24% | -4.02% | +2.20% | +7.28% | 1.32TCr | |
| +1.82% | +1.56% | -9.75% | -30.15% | 1.29TCr | |
| Average | +0.01% | +2.77% | +55.42% | +108.06% | 2.74TCr | |
| Weighted average by Cap. | +0.24% | +2.94% | +74.06% | +136.29% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 18Cr 20Cr 16Cr 15Cr 28Cr 1.92TCr 29Cr 194.63Cr 76Cr 947.5Cr 75Cr 73Cr 3.27TCr | - |
| Net income | 1.16Cr 1.32Cr 1.08Cr 99.17L 1.86Cr 126.54Cr 1.89Cr 13Cr 5.01Cr 62Cr 4.95Cr 4.85Cr 215.97Cr | - |
| Net Debt | -3.2Cr -3.64Cr -2.98Cr -2.74Cr -5.14Cr -349.08Cr -5.2Cr -35Cr -14Cr -172.37Cr -14Cr -13Cr -595.77Cr | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
